ArticleTissue engineering. Part A2015
Dual-phase osteogenic and vasculogenic engineered tissue for bone formation.
Article in Tissue engineering. Part A, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Durable reconstitution of sinonasal epithelium by transplant of CFTR gene corrected airway stem cells.bioRxiv : the preprint server for biology · 2025Article
- Developing anFrontiers in immunology · 2025Article
- Scaffold Guided Bone Regeneration for the Treatment of Large Segmental Defects in Long Bones.Biomedicines · 2023Review
- Multimodular vascularized bone construct comprised of vasculogenic and osteogenic microtissues.Biotechnology and bioengineering · 2022Article
- Fabrication and characterization of osteogenic function of progenitor cell-laden gelatin microcarriers.Journal of biomedical materials research. Part B, Applied biomaterials · 2022Article
- Coculture of Endothelial and Stromal Cells to Promote Concurrent Osteogenesis and Vasculogenesis.Tissue engineering. Part A · 2021Article
- Induced Pluripotent Stem Cell-Derived Endothelial Networks Accelerate Vascularization But Not Bone Regeneration.Tissue engineering. Part A · 2021Article
- Article
- Injectable osteogenic microtissues containing mesenchymal stromal cells conformally fill and repair critical-size defects.Biomaterials · 2019Article
- 3D human bone marrow stromal and endothelial cell spheres promote bone healing in an osteogenic niche.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Engineering in-vitro stem cell-based vascularized bone models for drug screening and predictive toxicology.Stem cell research & therapy · 2018Review
- Vascular Network Formation by Human Microvascular Endothelial Cells in Modular Fibrin Microtissues.ACS biomaterials science & engineering · 2016Article
- Synergistic enhancement of ectopic bone formation by supplementation of freshly isolated marrow cells with purified MSC in collagen-chitosan hydrogel microbeads.Connective tissue research · 2016Article
- Inosculation and perfusion of pre-vascularized tissue patches containing aligned human microvessels after myocardial infarction.Biomaterials · 2016Article
- Collagen Type II enhances chondrogenic differentiation in agarose-based modular microtissues.Cytotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Minimally invasive, injectable bone tissue engineering therapies offer the potential to facilitate orthopedic repair procedures, including in indications where enhanced bone regeneration is needed for complete healing. In this study, we developed a dual-phase tissue construct consisting of osteogenic (Osteo) and vasculogenic (Vasculo) components. A modular tissue engineering approach was used to create collagen/fibrin/hydroxyapatite (COL/FIB/HA) hydrogel microbeads containing embedded human bone marrow-derived mesenchymal stem cells (bmMSC). These microbeads were predifferentiated toward the osteogenic lineage in vitro for 14 days, and they were then embedded within a COL/FIB vasculogenic phase containing a coculture of undifferentiated bmMSC and human umbilical vein endothelial cells (HUVEC). In vitro studies demonstrated homogenous dispersion of microbeads within the outer phase, with endothelial network formation around the microbeads over 14 days in the coculture conditions. Subcutaneous injection into immunodeficient mice was used to investigate the ability of dual-phase (Osteo+Vasculo) and control (Osteo, Vasculo, Blank) constructs to form neovasculature and ectopic bone. Laser Doppler imaging demonstrated blood perfusion through all constructs at 1, 4, and 8 weeks postimplantation. Histological quantification of total vessel density showed no significant differences between the conditions. Microcomputed tomography indicated significantly higher ectopic bone volume (BV) in the Osteo condition at 4 weeks. At 8 weeks both the Osteo and Blank groups exhibited higher BV compared to the Vasculo and dual Osteo+Vasculo groups. These data not only show that osteogenic microbeads can be used to induce ectopic bone formation, but also suggest an inhibitory effect on BV when undifferentiated bmMSC and HUVEC were included in dual-phase constructs. This work may lead to improved methods for engineering vascularized bone tissue, and to injectable therapies for the treatment of orthopedic pathologies in which bone regeneration is delayed or prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.